The NPM1 mutation may also be used to monitor AML patients for residual disease during chemotherapy. Stratification of AML patients is also necessary for anti-AML drug clinical trials.
Xenomics has nonexclusively sublicensed its diagnostic applications to Warnex to offer clinical testing. The diagnostic test will help physicians select patients with a good prognosis of benefiting from intensive chemotherapy, while sparing others with a low probability of benefit from the toxic treatment.